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httpcense.Abstract Background: Hepatitis C virus (HCV) infection is associated with a wide series of extra-
hepatic manifestations. Pulmonary involvement is one of the extrahepatic manifestations of chronic
hepatitis C virus (HCV) infection. The objective of this study was to determine the impact of HCV
infection and the degree of liver dysfunction in patients with chronic obstructive pulmonary disease
(COPD).
Methods: This study was conducted on COPD patients. They were selected from outpatient
chest clinic in the Menouﬁa University Hospital. They were classiﬁed into 2 groups the ﬁrst group
COPD patients (n= 40) without hepatitis C and the second group COPD patients with chronic
hepatitis C. Second group (COPD with HCV) classiﬁed into 3 subgroups according Child–Pugh
classiﬁcation to determine the degree of liver insufﬁciency. Group IIA: patients Child–Pugh (A),
group IIB: patients Child–Pugh (B) and group IIC: patients Child–Pugh (C). The following pul-
monary function parameters were recorded: Forced Expiratory Volume in the ﬁrst second
(FEV1), Forced Expiratory Volume percent (FEV1/FVC%), Forced Expiratory Flow 25–75%
(FEF 25–75%) and Maximal Voluntary Ventilation (MVV).
Results: The study included 80 patients with COPD, 40 patients without chronic HCV infection
(group I), and 40 patients with chronic HBV infection (group II).COPD patients with HCV infec-
tion have increased deterioration in pulmonary function (FEV1, FEV1/FVC, FEF 25–75% andest Department, Menouﬁya
le: +20 1112143143.
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82 M.M. El-Habashy et al.MVV) than COPD patients without HCV infection. Also there were signiﬁcant decreases in pul-
monary function tests (FEV1, FEV1/FVC, FEF 25–75% and MVV) in group II subgroups IIA,
IIB and IIC according to the degree of decompensation.
Conclusion: Patients with COPD with HCV infection, have increased deterioration in pulmon-
ary function than patients with COPD without HCV infection and the deterioration increases with
hepatitis decompensation.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.Introduction
Worldwide, HCV is a common cause of chronic liver disease,
and a risk factor for liver cirrhosis and hepatocellular carci-
noma [1]. This viral infection can also be complicated by a
number of extrahepatic manifestations and has been associated
with both obstructive and restrictive lung disease [2].
More than 170 million people worldwide are chronically in-
fected by the HCV [3]. The Egyptian Demographic Health Sur-
vey (EDHS), a cross sectional survey including hepatitis C virus
biomarkers, was conducted in 2008 on a large nationally repre-
sentative sample. It estimated HCV prevalence among the
15–59 years age group to be 14.7% [4]. Around 30% to 70%
of patients with chronic hepatitis C have an extrahepatic
manifestation of HCV during the course of the disease [5].
Chronic obstructive pulmonary diseases (COPD 0 is the 4th
leading cause of death worldwide; its mortality is rising, while
cardiovascular disease’s is falling; COPD is expected to be the
3rd leading cause of death in the next 20 years [6].
Chronic infection with hepatitis HCV is to cause intra- and
extra-hepatic complications. Among the extra-hepatic compli-
cations, the lung is one major target organ [7]. Kanazawa et al
reported an accelerated decline of lung function in COPD
patients with concomitant hepatitis C infection. They have
suggested that the airway disease may be related to the under-
lying chronic inﬂammatory disorder [2].
Aim of study
To study the impact and effect of liver insufﬁciency of HCV
infection on patients with chronic obstructive pulmonary
diseases.
Patients and methods
This study was conducted on 80 COPD patients. They were se-
lected from outpatient chest clinic in the Menouﬁya University
Hospital. They were classiﬁed into 2 groups the ﬁrst group
COPD patients without chronic hepatitis C group I (n= 40)
and the second group COPD patients with chronic hepatitis
C group II (n= 40). All study subjects gave their written in-
formed consent for participation in this study.
These patients were conducted through the following:
(I) History: takinghistory of the patients to clear the presence
of hepatitis C infection. Past history of smoking and its
duration was documented, DM and hypertension.
(II) Clinical examination: all participants were examined to
clear the presence of jaundice, cyanosis, lower limb
oedema and ascites.(III) Laboratory investigations: all participants underwent a
group of lab tests:
(1) HCV antibody.
(2) HCV RNA by PCR to document HCV infection in
HCV positive patients.
(3) Alanine aminotransferase (ALT).
(4) Aspartate aminotransferase (AST).
(5) Total serum bilirubin.
(6) Serum albumin.
(7) Prothrombin time and concentration, INR (Interna-
tional normalized ratio was calculated for each patient).
(IV) Radiological investigation:
(1) Abdominal ultrasound
(2) Chest X-ray postero-anterior view
(3) Echocardiography and ECG
(V) Pulmonary function tests;
Spirometry was performed in all patients which measured
FEV1, FEV1/FVC, FEF 25–75% and MVV.
COPD patients with chronic hepatitis C patients were clas-
siﬁed to three groups according to Child–Pugh classiﬁcation to
determine the degree of liver insufﬁciency [8]: group IIA:
patients Child–Pugh A 16 patients, group IIB: patients
Child–Pugh B 10 patients and group IIC: patients Child–Pugh
C 14 patients. The score employs ﬁve clinical measures of liver
disease. Each measure is scored 1–3, with 3 indicating most
severe derangement.
Child–Pugh score.
Measure 1 Point 2 Points 3 Points
Total bilirubin,
lmol/l (mg/dl)
<34 (<2) 34–50 (2–3) >50 (>3)
Serum albumin
(g/l)
>35 28–35 <28
PT INR <1.7 1.71–2.30 >2.30
Ascites None Mild Moderate to
severe
Hepatic
encephalopathy
None Grade I–II (or
suppressed with
medication)
Grade III–IV
(or refractory)Exclusion criteria:
(1) Patients with cardiac diseases for example valvular heart
disease.
(2) COPD in exacerbation.
(3) Patients with a history of alcohol intake or active con-
sumption of alcohol.
(4) Patients with focal hepatic lesions or with malignancy
anywhere.
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(6) Patients with pleural effusion.
(7) Patients with renal failure.
Statistical analysis: statistical analyses were performed by
SPSS ver 13.0 for Windows (SPSS Inc, Chicago IL, US).
Univariate methods included a Student’s t test to compare
means of groups for continuous variables, and |c|2 analysis
for categorical variables unless the Fisher’s exact test was
required for contingency tables-when more than 20% of the
expected values were less than ﬁve. P< 0.05 was considered
statistically signiﬁcant [9].Result
This study included 80 patients with COPD, 40 COPD patients
without chronic HCV infection (group I), and 40 COPD
patients with chronic HBV infection (group II). Group II
was classiﬁed into subgroups according to Child–Pugh score
(IIA, IIB and IIC). Table 1 shows demographic features of
COPD patients without chronic HCV infection (group I) and
COPD patients with chronic HCV infection (group II) accord-
ing to sex, smoking, DM and hypertension, no signiﬁcant dif-
ference between the two groups (P> 0.05).
Table 2 shows that there was a statistically signiﬁcant dif-
ference between groups I and II regarding FEV1, FEV1/FVC
(p< 0.05) but there was high signiﬁcant difference between
them regarding FEF25–75 and MVV (p< 0.001).
Table 3 and Fig. 1 show that there was a statistically signif-
icant difference between groups II subgroups (IIA, IIB and
IIC) according to Child score regarding FEV1%, FEF 25–
75% and MVV but there was no signiﬁcant difference between
group IIA to IIC and IIB to IIC regarding FEV1 /FVC% andTable 2 Comparison between group I and group II according to p
HCVve COPD (mean ± SD)
FEV1/FVC% pred. 66.80 ± 4.32
FEV1% pred. 66.96 ± 3.72
FEF 25–75% pred. 48.16 ± 3.17
MVV% pred. 68.04 ± 6.3
Table 1 Demographic features of patients with COPD (group I) an
Demographic data HCVve COPD H
No % N
Sex Male 33 41.3 3
Female 7 8.8 6
Smoking Positive 30 37.5 2
Negative 10 12.5 1
DM Positive 16 20.0 1
Negative 24 30.0 2
HTN Positive 25 31.3 1
Negative 15 18.8 2
Age (mean ± SD) 46.2 ± 7.9 4there was signiﬁcant difference between IIA and IIB according
FEV1/FVC%.
Discussion
It is well-known that patients with HCV infection are at higher
risk for development of some extrahepatic conditions. While
the association of some extrahepatic conditions with HCV is
very clear, for some conditions, the association is strongly sus-
pected and for other conditions it is based only on some anec-
dotal data [10].
Our study revealed that COPD patients associated with
chronic HCV infection have signiﬁcant decrease in pulmonary
function compared with COPD patients. These ﬁndings sug-
gest that chronic HCV infection is associated with accelerated
decline of lung function in patients with COPD. This agrees
with study by Saetta et al., they found a decline of pulmonary
function in COPD patients associated with HCV infection [11].
Also Kanazawa et al., [2] reported an accelerated decline of
lung function in COPD patients with concomitant hepatitis
C infection. They have suggested that the airway disease may
be related to the underlying chronic inﬂammatory disorder.
It is also possible that the number and importance of different
inﬂammatory hits may change as the airway disease evolves.
Severe COPD is associated with the development of lymphoid
follicles in the small airways, implying the presence of an adap-
tive immune response. This immune response could be due to
chronic infection or the exposure of auto-antigens as a result of
increasing tissue damage. The extent to which the coexistence
of more than one acute or chronic inﬂammatory stimulus
produces additive or synergistic effects [12].
The general principle that the coexistence of multiple
inﬂammatory stimuli produces a more severe inﬂammatory re-
sponse might also apply to acute inﬂammatory stimuli. Thisulmonary function tests.
HCV+ve COPD (mean ± SD) t Test P value
56.46 ± 7.49 6.06 <0.05
54.69 ± 7.00 7.766 <0.05
46.23 ± 3.87 1.943 <0.001
54.7 ± 3.9 11.37 <0.001
d COPD with chronic HCV infection (group II).
CV+ve COPD Fisher’s exact test P value
o %
4 42.5 0.009 >0.05
7.5
7 33.8 0.001 >0.05
3 16.3
9 23.8 0.002 >0.05
1 26.3
8 22.5 2.46 >0.05
2 27.5
4.6 ± 7.5 t test 0.4 >0.05
Table 3 Comparison between group II subgroups (IIA, IIB and IIC) according to pulmonary function tests.
Group II HCV+ve COPD LSD test P value
IIA IIB IIC
FEV1/FVC. 64.2 ± 1.8 56.7 ± 2.7 62.8 ± 6.06 112.890 P1 6 0.05
P2P 0.05
P3P 0.05
FEV1% pred. 60.94 ± 3.67 51.33 ± 5.43 50.78 ± 5.09 13.506 P1 6 0.01
P2 6 0.01
P3 6 0.05
FEF 25–75% pred. 48.33 ± 3.14 45.5 ± 4.03 43.92 ± 3.2 4.046 P1 6 0.05
P2 6 0.001
P3 6 0.05
MVVl% pred. 57.42 ± 3.23 55.45 ± 2.33 50.8 ± 1.45 18.664 P1 6 0.05
P2 6 0.001
P3 6 0.001
P1ﬁ IIA–IIB, P2ﬁ IIA–IIC and P3ﬁ IIB–IIC.
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Figure 1 Comparison between group II subgroups (IIA, IIB and IIC) according to pulmonary function tests.
84 M.M. El-Habashy et al.mechanism might be particularly important in the develop-
ment of exacerbations of asthma and COPD [13]. Chronic liver
disorder decreases glutathione synthesis in the liver, and an
inadequate supply of glutathione in the lung would render
the lung vulnerable to oxidative damage [14].
Our study showed that there was a statistically signiﬁcant
difference between groups II subgroups (IIA, IIB and IIC)
according to Child score regarding FEV1%, FEF 25–75%
and MVV but there was no signiﬁcant difference between
group IIA to IIC and IIB to IIC regarding FEV1/FVC%
and this is due to a decrease in FVC(due to presence of ascites
which impairs diaphragmatic movement decreasing lung vol-
umes) more than a decrease in FV1 and this leads to preserva-
tion of the FEV1/FVC% ratio so they were not affected as in
group II A and B. and there was a signiﬁcant difference
between IIA and IIB according to FEV1/FVC%. This agrees
with Yigit et al., they found that among the PFT parameters,
FEV1/FVC and FEF 25–75% values were found to be lower in
patients with ascites than those without (P< 0.05) [15].
A previous study reported that numbers of lymphocytes in
bronchoalveolar lavage (BAL) ﬂuid are increased in patients
with chronic HCV infection, suggesting that HCV infection
might be a trigger of the development of lymphocyte alveolitis
[16]. These ﬁndings suggest that cytotoxic T lymphocytes in-
duced by chronic HCV infection may contribute to the devel-
opment of parenchymal lung destruction.Conclusion
Lung complications may occur as a result of hepatic disease
from any cause and represent a highly heterogeneous group
of conditions. Early recognition of such complications may
be challenging but is crucial both in forming a meaningful dif-
ferential diagnosis and in avoiding severe sequelae and irre-
versible damage. Patients with COPD with HCV infection,
have increased deterioration in pulmonary function than pa-
tients with COPD without HCV infection and the deteriora-
tion increases with hepatitis decompensation.Conﬂict of interest
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